2016 TOWARDS AN HIV CURE SYMPOSIUM

16 & 17 JULY 2016
DURBAN, SOUTH AFRICA

DURBAN INTERNATIONAL CONVENTION CENTRE (ICC)
The IAS would like to thank the following organizations for their generous support to the 2016 Towards an HIV Cure Symposium.
# TABLE OF CONTENTS

| Welcome Statement | 4 |
| 2016 Programme Committee | 5 |
| **16 July 2016** | 6 |
| Opening Session | 6 |
| Ethics and Social Sciences in HIV Cure Research | 6 |
| Special Session: Paediatric HIV Cure Research | 7 |
| Poster Exhibition & Networking Session | 7 |
| **17 July 2016** | 8 |
| HIV Latency and Reversal Strategies | 8 |
| Gene and Cell-Based Therapy | 9 |
| Roundtable: Bridging Biomedical Research and Social Sciences Towards an HIV Cure | 10 |
| Immunology of HIV Persistence | 10 |
| Closing Session | 11 |
| Poster Exhibition | 12 |
| Scholarship & Award Recipients | 20 |
| Timeline | 23 |
| Programme at a Glance | 24 |

---

**Continuing Medical Education Credits (CME)**

The scientific program of the 2016 Towards an HIV Cure Symposium has been reviewed by the American Medical Association (AMA) and approved for AMA PRA Category 1 Credit™. The American Medical Association will have a booth located on Ground Level, in the ICC Main Entrance.
Dear Colleagues,

On behalf of the International AIDS Society (IAS), the 2016 Programme Committee, and all members of the Towards an HIV Cure initiative, it is our pleasure to welcome you to Durban, South Africa, for the annual Towards an HIV Cure Symposium.

The search for a curative strategy for HIV is a goal of paramount importance and the area is increasingly being defined as a key priority for the future of HIV research. With that in mind, we are delighted to convene the 2016 Towards an HIV Cure Symposium, in its fifth year, to exchange and increase knowledge on the latest research towards remission or cure for HIV. We are also delighted on this occasion to launch the IAS Global Scientific Strategy: Towards an HIV Cure 2016, which outlines the current basic, translational and clinical research priorities, whilst also focusing on social sciences, ethics and research in resource-limited settings.

The symposium programme will provide a platform for broader discussion and interactive engagement on key topics in the HIV cure field through invited speaker presentations, abstract driven sessions, poster exhibition sessions, and roundtable discussions. Further, in 2016, for the first time, the Towards an HIV Cure Symposium is collaborating with the International Workshop on HIV Paediatrics to convene a special joint session on paediatric HIV cure research, followed by a networking reception.

The format of the symposium, purposely limited to 300 participants, is designed to provide an invaluable opportunity for information sharing, debate, and networking among scientists, clinical researchers, representatives of funding agencies, and the community involved in HIV cure research world-wide. The symposium places strong emphasis on ensuring representation of scientific excellence and community globally, with scholarships being provided to more than 60 participants worldwide.

We are confident that once again the symposium will be a platform where the international HIV/AIDS community will continue to dialogue and engage with their peers and foster collaborative relationships.

In order to share the information from the symposium, the abstracts will be published on the IAS website.

We look forward to a stimulating and productive meeting.

Sincerely,

Pr. Francoise Barre Sinoussi
Symposium Co-Chair

Dr. Steven Deeks
Symposium Co-Chair

Pr. Sharon Lewin
Symposium Co-Chair
## 2016 Programme Committee

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Position</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Françoise Barré-Sinoussi (Chair)</td>
<td>Institut Pasteur</td>
<td>France</td>
</tr>
<tr>
<td>Steven Deeks (Chair)</td>
<td>University of California, San Francisco</td>
<td>USA</td>
</tr>
<tr>
<td>Sharon Lewin (Chair)</td>
<td>The Doherty Institute, University of Melbourne</td>
<td>Australia</td>
</tr>
<tr>
<td>Jintanat Ananworanich</td>
<td>US Military HIV Research Program</td>
<td>USA</td>
</tr>
<tr>
<td>Nicolas Chomont</td>
<td>University of Montreal</td>
<td>Canada</td>
</tr>
<tr>
<td>Philip Goulder</td>
<td>University of Oxford</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Hans-Peter Kiem</td>
<td>Fred Hutchinson Cancer Research Center</td>
<td>USA</td>
</tr>
<tr>
<td>David Margolis</td>
<td>University of North Carolina at Chapel Hill</td>
<td>USA</td>
</tr>
<tr>
<td>Graeme Meintjes</td>
<td>UCT Faculty of Health Sciences</td>
<td>South Africa</td>
</tr>
<tr>
<td>Lynn Morris</td>
<td>National Institute for Communicable Diseases</td>
<td>South Africa</td>
</tr>
<tr>
<td>Michaela Muller-Trutwin</td>
<td>Institut Pasteur</td>
<td>France</td>
</tr>
<tr>
<td>Dianne Rausch</td>
<td>National Institute of Mental Health, NIH</td>
<td>USA</td>
</tr>
<tr>
<td>Matthew Sharp</td>
<td>Independent HIV Education and Advocacy Consultant</td>
<td>USA</td>
</tr>
<tr>
<td>Jerome Singh</td>
<td>Nelson R. Mandela School of Medicine</td>
<td>South Africa</td>
</tr>
<tr>
<td>Annette Sohn</td>
<td>TREAT Asia, amfAR</td>
<td>Thailand</td>
</tr>
<tr>
<td>Bruno Spire</td>
<td>Inserm</td>
<td>France</td>
</tr>
<tr>
<td>Bruce Walker</td>
<td>Ragon Institute of MGH, MIT and Harvard</td>
<td>USA</td>
</tr>
</tbody>
</table>

### Scientific coordination

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Position</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anna Laura Ross</td>
<td>ANRS and IAS</td>
<td>France</td>
</tr>
</tbody>
</table>

### Event organization

<table>
<thead>
<tr>
<th>Name</th>
<th>Institution/Position</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rosanne Lamplough</td>
<td>IAS</td>
<td>Switzerland</td>
</tr>
</tbody>
</table>
# 16 JULY 2016

## 14.00 – 15.00 Opening Session

Chair: Sharon Lewin, The Doherty Institute, University of Melbourne, Australia

### 14.00 – 14.15 Welcome and Introduction

Françoise Barré-Sinoussi, France  
Jack Whitescarver, United States

### 14.15 – 14.45 Keynote Address

**Addressing HIV Persistence: Challenges and Opportunities**  
Anthony Fauci, National Institute of Allergy and Infectious Diseases, NIH, United States

### 14.45 – 15.00 Community Speaker

**Moving Towards AIDS Cure: Community Partnerships**  
Gethwana Mahlase, ZimnadiZonke, South Africa

## 15.00 – 16.05 Ethics and Social Sciences in HIV Cure Research

Co-Chairs:  
Dianne Rausch, National Institute of Mental Health, NIH, United States  
Nir Eyal, Harvard TH Chan School of Public Health, United States

### 15.00 – 15.20: Overview Speaker

**Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa**  
Andrew Phillips, University College London, United Kingdom

### 15.20 – 15.35: OA1-1

**Unanticipated participant benefits in HIV cure clinical research: A qualitative analysis**  
A. Gilbertson, S. Rennie, E. Kelly, J. Kuruc, J. Tucker  
United States

### 15.35 – 15.50: OA1-2

**Ethical and social implications of proposed HIV cure research: stakeholder perspectives from South Africa**  
K. Moodley, Z. Duby, C. Staunton, M. Hendricks, G. Nair, M. de Roubaix, D. Skinner  
South Africa

### 15.50 – 16.05: OA1-3

**Factors Affecting Participation in HIV Cure-Related Research in the United States: Implications for Effective and Ethical Implementation**  
United States
16.05 – 16.30  COFFEE BREAK

16.30 – 18.00  Special Session: Paediatric HIV Cure Research

In collaboration with the 8th International Workshop on HIV Paediatrics
Chair: Deborah Persaud, Johns Hopkins University, United States

16.30 – 16.55: Overview Speakers

Neonatal and Paediatric Immunology relevant to HIV Persistence
Deena Gibbons, King’s College London, United Kingdom
Nigel Klein, University College London, United Kingdom

16.55 – 17.50: Roundtable Discussion – Research Priorities in Paediatric HIV Cure

Moderator:
Jintanat Ananworanich, US Military HIV Research Program, United States

Panelists:
Paolo Rossi, University of Rome, Italy
Thanyawee Puthanakit, Chulalongkorn University, Thailand
Barbara Kingsley, HIV Activist, South Africa
Diana Finzi, National Institute of Allergy and Infectious Diseases, NIH, United States
Caroline Tiemessen, National Institute for Communicable Diseases, South Africa

17.50 – 18.00: Concluding Remarks

18.00 – 19.30  Poster Exhibition & Networking Session

During the poster session, we invite you to meet and discuss with the HIV Cure 2016 scholars. The scholarship recipients can be identified by their white ribbon badge; the full list of scholarship recipients can be found on page 20.

Drinks and light refreshments will be served.
17 JULY 2016

9.00 – 10.35  HIV Latency and Reversal Strategies

Co-Chairs:
Carl Dieffenbach, Division of AIDS, NIAID, NIH, United States
Lynn Morris, National Institute for Communicable Diseases, South Africa

9.00 – 9.20: Overview Speaker

Addressing Key Gaps in Cure Research through Identification and Treatment of Hyperacute HIV Infection in a Resource-Limited Setting
Thumbi Ndung’u, University of KwaZulu-Natal, South Africa

9.20 – 9.35: OA2-1

Frequent and ‘burst-like’ reactivation from latency in SIVmac239M infected macaques
Australia

9.35 – 9.50: OA2-2

Cell-associated HIV-1 unspliced RNA level predicts both time to virological suppression and duration of post-treatment virological control in patients treated with temporary early ART
A. Pasternak, J. Prins, B. Berkhout
Netherlands

9.50 – 10.05: OA2-3

BCL-2 antagonism decreases HIV replication and infected cell survival in acute in vitro infection
N. Cummins, A. Sainksi, S. Natesampillai, S. Rizza, S. Kaufmann, A. Badley
United States

10.05 – 10.20: OA2-4

Enhancing HIV-1 Virion Tethering by BST2/Tetherin Sensitizes Productively and Latently Infected T cells to ADCC Mediated by Broadly Neutralizing anti-HIV Antibodies
T. N.Q Pham, S. Lukhele, É.A. Cohen
Canada

10.20 – 10.35: OA2-5 LB

No Evidence of Ongoing Replication in Tissue Compartments During Combination Antiretroviral Therapy
United States

10.35 – 11.00  Coffee Break
11.00 – 12.35  Novel Strategies for HIV Cure

Co-Chairs:
Daniel Kuritzkes, Brigham & Women's Hospital, Harvard Medical School, United States
Silvija Staprans, Bill & Melinda Gates Foundation, United States

11.00 – 11.20: Overview Speaker

How Can Oncology Help HIV Cure Strategies?
Olivier Lambotte, APHP - Hôpital Bicêtre, France

11.20 – 11.35: OA3-1

Allogeneic Stem Cell Transplantation in HIV-1 Infected Individuals; the EpiStem Consortium

11.35 – 11.50: OA3-2

CCR5 Gene Edited Cells Traffic to Viral Reservoir Tissues and Undergo SHIV-Dependent Positive Selection in Nonhuman Primates
United States

11.50 – 12.05: OA3-3

Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle can prevent the selection of resistance
M. Nijhuis, D. de Jong, F. Wolters, E. Wiertz, R.J. Lebbink
Netherlands

12.05 – 12.20: OA3-4 LB

Elimination of HIV-1 latently infected cells by PKC agonist gnidimacrin alone and in combination with a histone deacetylase inhibitor
United States

12.20 – 12.35: OA3-5 LB

Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals initiating ART during acute HIV infection
Thailand and United States

12.35 – 14.00  LUNCH BREAK & POSTER EXHIBITION

Lunch vouchers are provided for a hot food buffet in the Central Commissary, Lower Level.
14.00 – 15.00 Roundtable: Bridging Biomedical Research and Social Sciences Towards an HIV Cure

Chair: Judith Auerbach, University of California, San Francisco, United States
Panelists:
Moses Supercharger Nsubuga, Joint Clinical Research Centre, Uganda
Jerome Singh, Nelson R. Mandela School of Medicine, South Africa
Peter Newman, University of Toronto, Canada
Monique Nijhuis, University Medical Center Utrecht, Netherlands

15.00 – 15.25 Coffee Break

15.25 – 17.00 Immunology of HIV Persistence

Co-Chairs:
Zabrina Brumme, Simon Fraser University, Canada
Asier Saez-Cirion, Institut Pasteur, France

15.25 – 15.45: Overview Speaker
The Role of B Cell Follicles in HIV Replication and Persistence
Elizabeth Connick, University of Arizona, United States

15.45 – 16.00: OA4-1
Heterodimeric IL-15 induces effector cell activation and trafficking to the Germinal Centers of SIV infected Macaques
G.N. Pavlakis, A. Valentin, D.C. Watson, E. Moysi, C. Petrovos, X. Hu, C. Bergamaschi, B.K. Felber
United States

16.00 – 16.15: OA4-2
HIV Persists in Colon and Blood CCR6+CD4+ T-Cells during ART
Canada

16.15 – 16.30: OA4-3
PD-1 blockade combined with ART improves SIV-specific CD8 T cell function and enhances control of pathogenic SIV after ART interruption
G. Mylvaganam, S. Hicks, B. Lawson, M. Nega, V. Velu, R. Ahmed, G. Freeman, R.R. Amara
United States

16.30 – 16.45: OA4-4
Latency reversing agents induce HIV-1 protein expression in latently infected cells for cytotoxic T-lymphocyte antiviral recognition and killing
A. Ruiz de Andrés, E. Jimenez, R. Peña, P. Goulder, B. Clotet, J. Garcia Prado
Spain
16.45 – 17.00: OA4-5 LB

SIV persistence in ART-treated infant rhesus macaques
United States

17.00 – 18.00 Closing Session

17.00 – 17.30: Closing Lecture
Chair: Steven Deeks, University of California, San Francisco, United States

Development and Reversal of T Cell Exhaustion
John Wherry, University of Pennsylvania, United States

17.30 – 17.45: IAS-ANRS Young Investigator Prize Ceremony

Information on the award can be found on page 22.
Presented by:
Jean-François Delfraissy, ANRS, France
Chris Beyrer, Johns Hopkins Bloomberg School of Public Health, United States

17.45 – 18.00: Closing Remarks

The educational activity, Special Session: Paediatric HIV Cure Research, is supported by an educational grant from ViiV Healthcare.

The programme faculty’s disclosure of financial interest or other affiliations with ViiV can be found below.

Jintanat Ananworanich
Honorarium received for participation in advisory meeting

Steven Deeks
Research support

Sharon Lewin
Research support, ongoing and paid to institution.
Involvement in educational meetings through chairing or speaking, complete and paid to institution.

Annette Sohn
Grants to institution

Thanyawee Puthanakit
Research grant
Viral diversity, phylogenetics and phylodynamics

1. Analysis of Intra-patient, Full Length HIV gag Sequences Identifies Regions of Variability
   E. Anderson, M. Gouzoulis, A. Ganesan, C. Rehm, S. Jones, F. Maldarelli
   United States

Antibody diversity and function

2. Increased interferon-alphaactivity may contribute to defects of B cells and antibody production caused by HIV-1 infection
   L.N. Abudulai, L. Cha, S. Fernandez, M. French
   Australia

Reverse transcription and integration

3. HIV infected patients with exceptional TCD4+ recovery during effective HAART present a distinct T CD4+ differentiation pattern, higher CD31neg naïve cells and a smaller HIV reservoir
   Mexico

HIV-1 controllers (including post-treatment controllers)

4. Post-treatment Control or Treated Controllers? The impact of ART on time to viral rebound in recent seroconverters
   United Kingdom

5. Identification of different HIV-controller phenotypes: looking for the right model of functional cure
   Spain

6. HIV Virological Controllers in an African Cohort
   Y. Moosa, N. Garrett, C. Gray, V. Naranbhai, C. Williamson, S. Abdool-Karim
   South Africa

Correlates of immune protection

7. Presence of HIV-1 C broadly neutralizing antibodies in pregnancy and at delivery
   T. Mduluza, S. Dzoro, K. Bedi, W.S. Mpoloka
   Zimbabwe
Viral mechanisms of HIV/SIV persistence and latency

8. IFNα activates latent HIV-1 in non-proliferating latently infected T-cells
   R.M. van der Sluis, N.A. Kumar, V.A. Evans, A.N. Harman, T. Mota, S. Tennakoon, P. Herzog,
   S.R. Lewin, P.U. Cameron
   Australia

9. HIV-1 Disrupts Mitochondrial Dynamics: Induces Fission and Mitophagy to
   Attenuate Apoptosis in Astrocyte (Late Breaker)
   D.S. Ojeda, J. Quarleri
   Argentina

Host cellular factors and latency

10. The interferon-inducible restriction factor TRIM22 contributes to HIV-1 latency
    F. Turrini, G. Poli, E. Vicenzi
    Italy

11. Identification of a new host cell HDAC complex that controls HIV latency
    through direct binding to the core promoter
    E. Wilhelm, M. Bédard, P. Lavigne, C. Hunter, B. Bell
    Canada

Cellular and tissue reservoirs of HIV/SIV

12. Persistence of HIV DNA in Seminal Plasma Fraction after ART among Men who
    have Sex with Men and Transgender Women in the Thailand Test &Treat Cohort
    E. Chuang, R. Wangkanya, S. Pattananchaiwit, T. Pankam, S. Pengnonyang, K. Pussadee, S.
    Nonenoy, D. Trachunthong, S. Kerr, B. Shiramizu, N. Phanuphak
    United States

13. Memory CD4+ T cells expressing HLA-DR contribute to HIV persistence during
    prolonged ART
    E. Lee, B. Hiener, P. Bacchetti, W. Shao, E. Boritz, D. Douek, R. Fromentin, T. Liegler, S.G.
    Deeks, F.M. Hecht, J. Milush, N. Chomont, S. Palmer
    Australia

14. Effect of Substances of Abuse on HIV DNA Decay during Antiretroviral Therapy
    Started During Early HIV Infection
    United States

15. Is the lung a site of productive HIV infection that persists through ART?
    D. Russell, D. Gludish, K. Jamb, H. Mwandumba
    United States

16. Whole-body SPECT in Vivo Imaging reveals delayed reconstitution of lymph-nodes, but not spleen, CD4 pools in long-term cART treated animals (Late Breaker)
    M. Di Mascio, S. Srinivasula, I. Kim, P. DeGrange, A. St. Claire, E. Gabriel, C. Paik, H.C. Lane
    United States
Measurement of HIV/SIV reservoirs

17. HIV proviral DNA quantification in a cohort of Japanese patients on long-term ART
   K. Stanoeva, A. König, A. Fukuda, Y. Kawanami, T. Kuwata, Y. Satou, S. Matsushita
   Japan

18. Initiation of ART within 24-48 hours of birth following in utero HIV infection - the
    Ucwaningo Lwabantwana Study
   J. Roider, B.P. Mbatia, D. Hlope, M. Muenchhoff, K. Sprenger, Y. Graza, J. van Lobenstein,
   R. Bhoola, M. Krishna, K. Spicer, T. Ndung’u, P. Goulder
   United Kingdom

19. Quantification and correlates of the replication competent HIV-1 latent viral
    reservoir in a virally suppressed Ugandan population.
   J.L. Prodger, J.D. Siliciano, J. Lai, S.J. Reynolds, J. Kasule, T. Kityamuweesi, D. Serwadda,
   A.D. Redd, R.F. Siliciano, R.D. Moore, T.C. Quinn
   United States

Targeting and eradication of reservoirs

20. Sirtuin1 Inhibitor Nicotinamide disrupts HIV-1 Latency
    S. Samer, T. Oshiro, J. Galinskas, M.C.S. Umaki, M.C. Sucupira, S. Tenori, A. Duarte, R.S. Diaz
    Brazil

21. T regulatory cell depletion in controller macaques reactivates SIV and boosts
    CTLs
   T. He, B. Policicchio, E. Brocca-Cofano, J. Stock, C. Xu, K. Raehetz, T. Gaufin, R. Gautam,
   I. Pandrea, C. Apetrei
   United States

22. Development of DOUBLE NICKASE CRISPR Aganist Latently Infected Human
    Immunodeficency Virus (HIV)
   O.A. Ishola, K. Theva Das
   Malaysia

23. Understanding the effects of latency reversing agents on HIV RNA splicing -
    implications for latency reversal
   T.M. Mota, G. Khoury, J.C. Jacobson, H.K. Lu, F. Wightman, R.M. Van der Sluis, J.L. Anderson,
   P.U. Cameron, S.R. Lewin, D.F.J. Purcell
   Australia

24. Thalidomide Reverses Latency of HIV-1 Provirus
    S. Samer, T. Oshiro, T. Vergara, J. Gakinskas, S. Tenori, M.C. Sucupira, A. Duarte, R.S. Diaz
    Brazil

25. Targeting HSF1-mediated stress response can enhance Hsp90 inhibitor-induced
    suppression of HIV-1 reactivation from latency
   A. Kabakov, E. Petrova, S. Sobenin
   Russian Federation
26. A novel assay to evaluate the response of patient-derived virus to latency-reversing agents ex vivo
   H. Lu, M. Moso, L. Gray, T. Mota, J. Jacobson, A. Ellett, W.-J. Cheng, D. Purcell, P. Cameron,
   M. Churchill, S. Lewin
   Australia

27. Therapeutic immune recovery prevents emergence of CXCR4-tropic HIV-1
   J. Bader, M. Daenouer, A. Thielen, F. Schoni-Affolter, J. Boeni, M. Gorgievski-Hrisoho,
   G. Martinetti, T. Klimkait, Swiss HIV Cohort Study
   Switzerland

28. Dendritic cells programmed by inflammatory mediators can effectively induce both the immunologic ‘kick’ and ‘kill’ of latent HIV-1
   J. Kristoff, R.B. Mailliard, J.M. Zerbato, N. Sluis-Cremer, M. Carlson, M. Ding, P. Gupta,
   C.R. Rinaldo
   United States

29. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels, and latent HIV infection
   P. Tsai, J.V. Garcia
   United States

30. Maraviroc administration is associated to reversion of latent HIV-1 through NFkB in ART suppressed patients (Late Breaker)
   N. Madrid-Elena, L. García-Bermejo, A. Díaz-De Santiago, S. Serrano-Villar, F. Dronda,
   B. Sastre-Turrón, C. Gutierrez, B. Hernández-Novoa, S. Moreno Guillén
   Spain

**Acute and early infection**

31. Systematic Review of the Current Literature on Structured Treatment Interruptions in HIV-infected Patients Receiving Antiretroviral Therapy - Implications for Future HIV Cure Trials
   Germany

32. Alarmin IL-33/ST2 pathway as an inductor of T-cell dependent response in acute and early HIV-infected patients
   J.-P. Routy, V. Mehraj, R. Thomas, J.-G. Baril, R. Leblanc, B. Lebouche, C. Costiniuk, C. Tremblay,
   M.-A. Jenabian, Montreal Primary HIV Infection Study Group
   Canada

**Novel approaches in Immunotherapeutics (including bnAbs and anti-inflammatory mediators)**

33. A novel bispecific immunoadhesin displays enhanced breadth and potency against diverse HIV-1 subtypes in vitro and in humanized mice
   X. Wu, J. Guo, M. An, Z. Chen
   Hong Kong
34. **Novel Conserved Element HIV/SIV DNA Vaccines Maximize Breadth and Magnitude of Immune Response**  
B.K. Felber, X. Hu, A. Valentin, F. Dayton, Y. Cai, M. Rosati, C. Alicea, N.Y. Sardesai, R. Gautam,  
M.A. Martin, J.I. Mullins, G.N. Pavlakis  
United States

**Targeting HIV persistence during ART (cure strategies)**

35. **Therapy with The Immunomodulatory Agent Pomalidomide Does Not Lead To Changes In HIV-1 Viral Populations In Vivo**  
S.A. Watters, M.N. Polizzotto, W. Shao, R. Gorelick, E.M. Anderson, I. Sereti, K. Aleman,  
L. Kouyoudjian, J.B. Zeldis, T. Uldrick, R. Yarchoan, F. Maldarelli  
United Kingdom

36. **Dose-dependent effects of HDACi on T cell activation and HIV latency reversal**  
X.T. Kuang, P. Mwimanzi, G. Anmole, M.A. Brockman  
Canada

37. **Novel pathways of Tat expression identify new targets for reactivation of latent HIV-1**  
M. Lee, J. Jacobson, M. Olshansky, T. Mota, S. Lewin, G. Khoury, S. Sonza, D. Purcell  
Australia

38. **Small molecule inhibitors of BAF; a new family of compounds in HIV-1 latency reversal**  
E. De Crijn, M. Stoszka, C. Rokx, M.M. Khalid, C. Lungu, R-J. Palstra, T-W. Kan, C. Boucher,  
A. Verbon, E.C. Dykhuizen, T. Mahmoudi  
Netherlands

39. **Novel activators and suppressors of latent HIV-1 from natural products**  
I. Tietjen, K. Andreae-Marobela, X.T. Kuang, G.W. Fotsos, D. Williams, A. Pagliuzza, B.M. Abegaz,  
R.J. Andersen, A. Cochrane, N. Chomont, Z.L. Brumme, M.A. Brockman  
Canada

40. **A systems dynamics approach to identifying novel HIV treatments**  
H. Yang, K. Eubanks, M. de Souza  
United States

41. **Vitamin D level in cART treated patients is critical for HIV reservoir size**  
A. Chéret, A. Pasquet, M. Lachatre, P. Dujardin, K. Bourdic, Y. Quertainmont, I. Alcaraz,  
F. Boufassa, C. Goujard, E. Sauzer, L. Bocquet, C. Rouzioux  
France

**Therapeutic vaccines**

42. **Characterization of Monocyte-Derived Dendritic Cells Used in Immunotherapy for HIV-1-infected Individuals**  
L. Teodoro da Silva, W. Cardoso da Silva, D. da Silva Reis, B. Tereso Santillo, P. Ordonhez  
Rigato, A. de Almeida, A. Jose da Silva Duarte, T. Miyuki Oshiro  
Brazil
43. SiRNA based TLR7/8 activation, MHC class I recycling from endosome and cross presentation of HIV-1 antigen for elevated CD8+ response: An approach for intracellular vaccine
A. Adhikari, B. Gupta
Nepal

44. Volunteer motivators for participating in HIV vaccine clinical trials in Nairobi, Kenya
B.A. Nyaoke, G. Mutua, R. Sajabi, D. Nyasani, O.A. Anzala
Kenya

45. HIV-tat fused to the oligomerisation domain of the c4-binding protein is highly immunogenic and controls EcoHIV challenge in mice
K. Tomusange, D. Wijesundara, J. Gummow, T. Garrod, Y. Li, L. Gray, M. Churchill,
B. Grubor-Bauk, E. James, Gowans
Australia

Novel animal/virus models for vaccine, cure research, and inhibitor development

46. A nonhuman primate model of fully MHC-matched allogeneic stem cell transplantation to study HIV reservoir clearance (Late Breaker)
B. Burwitz, J. Stanton, C. Shriver-Munsch, T. Swanson, A. Legasse, K. Hammond, S. Abdulhaqq,
H. Wu, R. Macallister, M. Axthelm, T. Hobbs, L. Martin, R. Ducore, A. Lewis, L. Colgin,
A. Panoskaltsis-Mortari, G. Meyers, R. Maziarz, J. Sacha
United States

Animal models of latency reservoirs and eradication

47. Immuno-PET/CT imaging reveals differences in virus and CD4+ cell localization in SIV infected rhesus macaques treated with an anti-α4β7 mab
J. Arthos, S. Byrareddy, C. Cicala, K. Ortiz, D. Little, S. Gumber, J.J. Hong, C. Zurla, F. Villinger,
A. Fauci, A. Ansari, P. Santangelo
United States

Acute and early infection

48. Faster restoration of CD4:CD8 ratio during the first 12 weeks of ART initiated at early HIV infection compared with ART initiated at chronic infection in the same patients
A. Pasternak, J. Prins, B. Berkhout
Netherlands

49. Using ddPCR to Assess Persistence of HIV DNA Reservoirs in Perinatally Infected Infants Treated with cART Before or After 12 Months of Age
P. Soni, L. Alderette, Y. Bryson
United States
50. Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection (Late Breaker)


Thailand

Ethical issues in clinical trials and treatment strategies

51. HIV patients and caregivers viewpoints towards participation to future HIV Cure-related clinical trials - results from the second part of the French ANRS-APSEC survey


France

52. How to keep high-risk early-phase HIV cure and long-term remission studies ethical: classifying candidate solutions

N. Eyal

United States

Social and behavioural concepts and theories

53. Perceptions of HIV remission (“cure”) trials and trial intentions among potential participants treated in acute HIV infection


Thailand

54. How curing HIV could influence stigma: a qualitative analysis of men who have sex with men in Guangzhou, China

F. Wu, A. Babbitt, Q. Ma, X. Pan, W. Cai, Y. Cheng, J. Tucker

China

Community engagement in research and research dissemination

55. “I can coexist with HIV”: a qualitative study of perceptions of HIV “cure” among people living with HIV in Guangzhou, China


China

Ethical aspects and standards, including with respect to research, clinical services, public health policy and programmes, and professional conduct

56. Is there an implementation ethics to HIV cure-related research?


United States
57. HIV Cure research: a survey of Australian people living with HIV on perspectives, perceived benefits and willingness to participate in trials
J. Power, J. Lucke, G. Dowsett, G. Brown, A. Lyons
Australia

58. Challenges in developing an educational video on HIV Cure research
South Africa

59. Interrupting HIV Treatment in Cure Research: Scientific and Ethical Considerations
United States

Full affiliations can be found in the abstract book, published in the Journal of Virus Eradication.
<table>
<thead>
<tr>
<th>Name</th>
<th>Institution</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melissa-Rose Hilda Abrahams</td>
<td>University of Cape Town</td>
<td>South Africa</td>
</tr>
<tr>
<td>Adefunke Adesope</td>
<td>National Primary Health Care Development Agency, Abuja</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Anurag Adhikari</td>
<td>Tribhuvan University</td>
<td>Nepal</td>
</tr>
<tr>
<td>Moises Agosto</td>
<td>National Minority AIDS Council (NMAC)</td>
<td>United States</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>National Cancer Institute</td>
<td>United States</td>
</tr>
<tr>
<td>Tamás Bereczky</td>
<td>European AIDS Treatment Group</td>
<td>Hungary</td>
</tr>
<tr>
<td>Craig Burnett</td>
<td>Victorian AIDS Council</td>
<td>Australia</td>
</tr>
<tr>
<td>Nehsuh Carine Alongfor</td>
<td>StopAIDS-Cameroon</td>
<td>Cameroon</td>
</tr>
<tr>
<td>Pelagia Nicholalily Chabata</td>
<td>Zimbabwe Community Health Intervention Research Project (ZICHIRE)</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Eleanore Chuang</td>
<td>Hawaii Center for AIDS, University of Hawaii</td>
<td>United States</td>
</tr>
<tr>
<td>Subathira Dakshina</td>
<td>Barts Health NHS Trust</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>John Ditekemena Dinangga</td>
<td>The Elizabeth Glaser Pediatric AIDS Foundation</td>
<td>Congo, The Democratic Republic of the</td>
</tr>
<tr>
<td>Beatriz Dominguez Molina</td>
<td>Institute of Biomedicine of Seville, Virgen del Rocio University Hospital</td>
<td>Spain</td>
</tr>
<tr>
<td>Luz Guiselly Flores Arroyo</td>
<td>Peruvian Network of Women with HIV/AIDS</td>
<td>Peru</td>
</tr>
<tr>
<td>Tianyu He</td>
<td>University of Pittsburgh</td>
<td>United States</td>
</tr>
<tr>
<td>Miriam Heck</td>
<td>Institute of Biochemistry</td>
<td>Germany</td>
</tr>
<tr>
<td>Oluwaseun Ayodeji Ishola</td>
<td>Advanced Medical and Dental Institute, Universiti Sains Malaysia</td>
<td>Malaysia</td>
</tr>
<tr>
<td>Alexander Kabakov</td>
<td>BioMedical Research Center BION</td>
<td>Russian Federation</td>
</tr>
<tr>
<td>Damian John Kelly</td>
<td>European AIDS Treatment Group</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Sandris Klavins</td>
<td>AGIHAS (PLWHA Support group)</td>
<td>Latvia</td>
</tr>
<tr>
<td>Catherine Kegakilwe Koofohthile</td>
<td>HIV Pathogenesis Programme (HPP), University of KwaZulu-Natal</td>
<td>South Africa</td>
</tr>
<tr>
<td>Jan Kristoff</td>
<td>University of Pittsburgh Graduate School of Public Health</td>
<td>United States</td>
</tr>
<tr>
<td>Xiao Mei Kuang</td>
<td>Simon Fraser University</td>
<td>Canada</td>
</tr>
<tr>
<td>Eunok Lee</td>
<td>The Westmead Institute for Medical Research, University of Sydney</td>
<td>Australia</td>
</tr>
<tr>
<td>Michelle Lee</td>
<td>Peter Doherty Institute/University of Melbourne</td>
<td>Australia</td>
</tr>
<tr>
<td>Genevieve Elizabeth Martin</td>
<td>Peter Medawar Building for Pathogen Research (University of Oxford)</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Colisile Nonduduzo Mathonsi</td>
<td>University of KwaZulu-Natal</td>
<td>South Africa</td>
</tr>
<tr>
<td>SCHOLARSHIP &amp; AWARD RECIPIENTS</td>
<td>University</td>
<td>Country</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>------------</td>
<td>---------</td>
</tr>
<tr>
<td>Taguma Allen Matubu</td>
<td>University of Zimbabwe- University of California San Francisco Collaborative Research Program</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Talkmore Taurai Mazorodze</td>
<td>Swaziland Network of Young Positives</td>
<td>Swaziland</td>
</tr>
<tr>
<td>Takafira Mduluza</td>
<td>University of Zimbabwe</td>
<td>Zimbabwe</td>
</tr>
<tr>
<td>Andile Mfene</td>
<td>Centre for the AIDS Programme of Research in South Africa (CAPRISA)</td>
<td>South Africa</td>
</tr>
<tr>
<td>Kopano Mmalane</td>
<td>Princess Marina Hospital</td>
<td>Botswana</td>
</tr>
<tr>
<td>Duncan Japhta Khothatso Moeke</td>
<td>National Association of People Living with HIV (NAPWA-SA)</td>
<td>South Africa</td>
</tr>
<tr>
<td>Yumna Moosa</td>
<td>Centre for the AIDS Programme of Research in South Africa (CAPRISA)</td>
<td>South Africa</td>
</tr>
<tr>
<td>José Moreira</td>
<td>Mozambique National Institute of Health (INS)</td>
<td>Brazil</td>
</tr>
<tr>
<td>Talia Mota</td>
<td>Doherty Institute for Infection and Immunity, University of Melbourne</td>
<td>Australia</td>
</tr>
<tr>
<td>Marvelous Muchenje</td>
<td>Women’s Health in Women’s Hands, CHC</td>
<td>Canada</td>
</tr>
<tr>
<td>Sylvia Nalubega</td>
<td>University of Nottingham</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Robert Newells</td>
<td>AIDS Project of the East Bay</td>
<td>United States</td>
</tr>
<tr>
<td>Jai NicAllen</td>
<td>StopAIDS; Terrence Higgins Trust</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Moses Supercharger Nsubuga</td>
<td>Joint Clinical Research Centre</td>
<td>Uganda</td>
</tr>
<tr>
<td>Borna Achieng Nyaoke</td>
<td>Kenya AIDS Vaccine Initiative (KAVI)-Institute of Clinical Research, University of Nairobi</td>
<td>Kenya</td>
</tr>
<tr>
<td>Judith Apondi Odhiambo</td>
<td>University</td>
<td>Canada</td>
</tr>
<tr>
<td>Abosede Oladayo</td>
<td>The Well Project</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Chinyere Onyia</td>
<td>Community Health and International Research Organisation (CHIRO)</td>
<td>Nigeria</td>
</tr>
<tr>
<td>Alexander Pasternak</td>
<td>Academic Medical Center of the University of Amsterdam</td>
<td>Netherlands</td>
</tr>
<tr>
<td>Santiago Perez</td>
<td>INCNMSZ</td>
<td>Mexico</td>
</tr>
<tr>
<td>Robert Reinhard</td>
<td>Institut de recherches cliniques de Montreal</td>
<td>Canada</td>
</tr>
<tr>
<td>Rachel Samantha Resop</td>
<td>University of California, Los Angeles</td>
<td>United States</td>
</tr>
<tr>
<td>Juan Pablo Rodríguez-Vásquez</td>
<td>Costa Rica National Network of Positive Youth (J+ CR)</td>
<td>Costa Rica</td>
</tr>
<tr>
<td>Alba Ruiz de Andrés</td>
<td>AIDS Research Institute IrsiCaixa</td>
<td>Spain</td>
</tr>
<tr>
<td>Talia Sainz</td>
<td>Hospital Infantil La Paz and CoRISpe</td>
<td>Spain</td>
</tr>
<tr>
<td>Sadia Samer</td>
<td>Federal University of Sao Paulo</td>
<td>Brazil</td>
</tr>
<tr>
<td>Priya Soni</td>
<td>UCLA - David Geffen School of Medicine</td>
<td>United States</td>
</tr>
</tbody>
</table>
# SCHOLARSHIP & AWARD RECIPIENTS

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation and Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Ssekubugu</td>
<td>Rakai Health Sciences Program, Uganda</td>
</tr>
<tr>
<td>Kamelia Stanoeva</td>
<td>Center for AIDS Research, Kumamoto University, Japan</td>
</tr>
<tr>
<td>Jeff Taylor</td>
<td>AIDS Treatment Activists Coalition, United States</td>
</tr>
<tr>
<td>Lais Teodoro Da Silva</td>
<td>Public organization, Brazil</td>
</tr>
<tr>
<td>João Paulo Toledo</td>
<td>Ministry of Health of Brazil, HIV/AIDS, STI and Viral Hepatitis Department, Brazil</td>
</tr>
<tr>
<td>Khamis Tomusange</td>
<td>University of Adelaide, Basil Hetzel Research Institute, Australia</td>
</tr>
<tr>
<td>Perry Tsai</td>
<td>UNC Chapel Hill Center for AIDS Research, United States</td>
</tr>
<tr>
<td>Mary Kangabe Tumushime</td>
<td>Centre for Sexual Health and HIV/AIDS Research (CeSHHAR), Zimbabwe</td>
</tr>
<tr>
<td>Filippo Turrini</td>
<td>Vita-Salute San Raffaele University, Italy</td>
</tr>
<tr>
<td>Renee Marije van der Sluis</td>
<td>Doherty Institute for Infection and Immunity, University of Melbourne, Australia</td>
</tr>
<tr>
<td>Sarah Watters</td>
<td>University College London, Division of Infection and Immunity, United Kingdom</td>
</tr>
<tr>
<td>Emmanuelle Wilhelm</td>
<td>Université de Sherbrooke, Canada</td>
</tr>
</tbody>
</table>

## IAS-ANRS HIV Cure Young Investigator Award

The US$2000 IAS/ANRS HIV Cure Young Investigator Award is jointly funded by the International AIDS Society (IAS) and the Agence National de Recherche sur le sida et les hépatites virales (ANRS) to support young researchers who demonstrate innovation, originality, rationale and quality in the field of HIV/AIDS research.
TIMELINE

July 2010
IAS workshop on HIV viral reservoirs: Towards a Cure: HIV reservoirs and strategies to control them

Spring 2011
Establishment of the 2011-2012 International Scientific Working Group to develop a Global Scientific Strategy

Early 2011
1st Stakeholders Advisory Board meeting

Summer 2011
Launch of the Rome Statement: Major HIV/AIDS Stakeholder’s call for HIV cure research to be accelerated

Early 2012
Establishment of the Working Group on Ethics, the Psychosocial Studies Group and the Industry Collaboration Group (ICG)

July 2012

Establishment of the Working Group on Cost-Effectiveness

May 2013
Towards an HIV Cure Think-Tank: Merging fields for innovative approaches, Paris

Ethical Considerations in HIV Cure Research: Points to Consider, published in Current Opinion in HIV and AIDS.

June 2013
2013 Towards an HIV Cure Symposium, Kuala Lumpur

Jan 2014
Towards an HIV Cure Community Engagement Workshop, Chennai

July 2014
2014 Towards an HIV Cure Symposium, Melbourne

Towards an HIV Cure: Community Engagement Satellite, Melbourne

Autumn 2014
Establishment of the 2015-2016 International Scientific Working Group to revise and update the Global Scientific Strategy

Help End AIDS Together: Towards Vaccine and Cure For HIV/AIDS Satellite, Cape Town

July 2015
2015 Towards an HIV Cure Symposium, Vancouver

Towards an HIV Cure: Canadian <-> Global Stakeholder’s Engagement Workshop, Vancouver

Autumn 2015
The HIV Cure Research Agenda: the Role of Mathematical Modelling and Cost-Effectiveness Analysis, published in Journal of Virus Eradication

Towards Multidisciplinary HIV-Cure Research: Integrating Social Science with Biomedical Research, published in Trends in Microbiology

Jan 2016
Launch of Material Transfer Agreement for Combinational Use of Marketed Compound in Anti-Retroviral Therapy (cMTA)

July 2016
Launch of the IAS Global Scientific Strategy: Towards an HIV Cure 2016 at the 2016 Symposium, Durban. Publication in Nature Medicine

Towards an HIV Cure: Engaging the Community Workshop and Understanding HIV Cure Workshop, Durban
<table>
<thead>
<tr>
<th>TIME</th>
<th>Saturday 16th July</th>
<th>Sunday 17th July</th>
<th>TIME</th>
</tr>
</thead>
<tbody>
<tr>
<td>9h00-10h35</td>
<td>S2: HIV Latency and Reversal Strategies</td>
<td></td>
<td>9h00-10h35</td>
</tr>
<tr>
<td></td>
<td>Invited Speaker: Thumbi Ndung’u</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10h35-11h00</td>
<td>Break</td>
<td></td>
<td>10h35-11h00</td>
</tr>
<tr>
<td>11h00-12h35</td>
<td>S3: Novel Strategies for HIV Cure</td>
<td></td>
<td>11h00-12h35</td>
</tr>
<tr>
<td></td>
<td>Invited Speaker: Olivier Lambotte</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12h35-14h00</td>
<td>Lunch Break and Poster Exhibition</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13h15-14h00</td>
<td>Registration</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14h00-14h15</td>
<td>Welcome Remarks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14h15-14h45</td>
<td>Special Guest Keynote: Anthony Fauci</td>
<td>Roundtable: Bridging Biomedical Research and Social Sciences Towards an HIV Cure</td>
<td>14h00-15h00</td>
</tr>
<tr>
<td>14h45-15h00</td>
<td>Invited Community Speaker: Gethwana Mahlase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15h00-16h05</td>
<td>S1: Ethics and Social Sciences in HIV Cure Research</td>
<td>S4: Immunology of HIV Persistence</td>
<td>15h00-15h25</td>
</tr>
<tr>
<td></td>
<td>Invited Speaker: Andrew Phillips</td>
<td>Invited Speaker: Elizabeth Connick</td>
<td></td>
</tr>
<tr>
<td>15h25-17h00</td>
<td>Break</td>
<td></td>
<td>15h25-17h00</td>
</tr>
<tr>
<td>16h05-16h30</td>
<td></td>
<td>Closing Address John Wherry</td>
<td>17h00-17h30</td>
</tr>
<tr>
<td>16h30-18h00</td>
<td>Special Session: Paediatric HIV Cure Research</td>
<td>IAS/ANRS HIV Cure Young Investigators Award and Closing Remarks</td>
<td>17h30-18h00</td>
</tr>
<tr>
<td>18h00-19h30</td>
<td>Poster Exhibition and Networking Session</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2016 Symposium Sponsors:

- National Institutes of Health (NIH)
- National Institute of Allergy and Infectious Diseases (NIH)
- Gilead
- ViiV Healthcare
- MSD
- Janssen
- France Récherche Nord & sud Sida-Hiv Hépatites
- Agence autonome de l'Inserm
- IAS

Office of AIDS Research